Modulators of cell cycle progression
AssigneeSingapore Health Services Pte Ltd
InventorsMeng Cheong Wong, Congju Zhu, Shi Yuan Cheng
Life of this patent
Estimating the term…
Abstract
Epithelial cell transforming sequence 2 (Ect2) is a potential oncogene. Our invention uncovers key mechanisms of Ect2 oncogenicity and the development of a relevant therapies by modulation of Ect2 expression.
Claims35
1-35. (canceled)
A method of inhibiting cell growth and cell cycle progression from G1 to S phase and increasing protein expression of p27kip1 by removing, degrading or neutralising the concentration of epithelial cell transforming sequence 2 (Ect2) in a cellular environment.
A method for treating a patient to at least reduce glioma growth, which comprises the step of:
- a. contacting the glioma with an antagonist to epithelial cell transforming sequence 2 (Ect2) wherein cell growth and cell cycle progression from G1 to S phase in the cells of the glioma are inhibited and protein expression of p27kip1 is increased
A composition comprising an antagonist of cell growth and cell cycle progression from G1 to S phase and an agonist of p27kip1 protein expression capable of removing, degrading or neutralising the concentration of epithelial cell transforming sequence 2 (Ect2).
A method of identifying an antagonist to cell growth and cell cycle progression from G1 to S phase comprising the steps of:
- a. contacting a cell culture with a sample compound;
- b. detecting the concentration of epithelial cell transforming sequence 2 (Ect2) and protein expression of p27kip1 in the cell;
- and
- c. detecting the concentration of Ect2 and the protein expression of p27kip1 in a second cell culture not contacted with the sample compound,
- whereby a decrease in the Ect2 concentration and an increase in protein expression of p27kip1 within the cell culture contacted with the sample compound in relation to the second cell culture indicates the sample compound is an antagonist.
Dependencies are inferred from the claim text.